Phase 3 Depression Programme APPROACHes a Defining Clinical Readout as Its Proprietary Serotonergic Pipeline Targets Lasting Treatment Benefits in Depression and Anxiety

Helus Pharma approaches a defining clinical milestone as its lead deuterated psilocin candidate, HLP003, advances through Phase 3 development for adjunctive major depressive disorder (MDD), supported by encouraging Phase 2a efficacy, durability signals and FDA Breakthrough Therapy Designation. The anticipated Q4 2026 APPROACH readout represents a major valuation catalyst, while HLP004’s revised Phase 2 monotherapy programme targets generalised anxiety disorder (GAD). Proprietary serotonergic chemistry, extensive patent protection and established development partnerships support potential differentiation in substantial psychiatric markets. Our risk-adjusted valuation of US$1.19 billion, or US$16.40 per share, remains principally driven by HLP003, with clinical validation, regulatory progress and financing central to future commercialisation.

1. 01

   HLP003 approaches a defining Phase 3 readout

   Topline results from the 223-participant APPROACH trial are expected in the fourth quarter of 2026. The Phase 3 program also includes EMBRACE, which evaluates two doses against placebo, and EXTEND, which assesses longer-term safety, durability, and retreatment. Results could support a targeted 2028 FDA filing, subject to trial success and regulatory review.

2. 02

   Phase 2a results provide an encouraging efficacy signal

   At Week 3, the 12 mg and 16 mg doses showed placebo-adjusted MADRS improvements of 14.11 and 12.99 points, respectively. In an uncontrolled 12-month follow-up, five of seven participants who received two 16 mg doses were in remission.

3. 03

   Deuterated chemistry and FDA designation support development

   HLP003 is a deuterated psilocin analogue designed to modify metabolism and exposure. FDA Breakthrough Therapy Designation supports enhanced regulatory engagement, while drug–drug interaction findings support further evaluation alongside existing antidepressants.

4. 04

   Unmet need creates an opportunity for an adjunctive treatment

   Approximately 19.7 million U.S. adults experienced a major depressive episode in 2025. An estimated 8,000 interventional psychiatry facilities across relevant categories could support delivery, while clinical eligibility, reimbursement, treatment capacity, and retreatment requirements will influence the addressable opportunity.

5. 05

   Intellectual property and HLP005 extend pipeline opportunities

   Helus reports more than 350 patent applications filed and over 100 patents granted. The company anticipates protection through at least 2042 for HLP003 and 2041 for HLP004, subject to patent scope and challenges. Its preclinical HLP005 program is targeting candidate selection in the second half of 2027.

6. 06

   HLP004 offers a second clinical opportunity in anxiety

   Helus plans an approximately 144-participant, placebo-controlled Phase 2 monotherapy study in generalized anxiety disorder to begin in the first quarter of 2027. The earlier study showed similar symptom improvements in the 20 mg and 2 mg active-dose groups.

7. 07

   Partnerships and leadership support execution

   Thermo Fisher Scientific provides HLP003 drug-substance and drug-product manufacturing capabilities for clinical supply, with a potential foundation for future commercial production. Helus's leadership has experience at Intra-Cellular Therapies, Eli Lilly, UCB, and AstraZeneca; regulatory validation, funding, and execution remain essential.

8. 08

   Product-level valuation is concentrated in HLP003

   In the preliminary product-level risk-adjusted net present value model, commercial-phase cash flows are weighted using success probabilities of 60% for HLP003 and 30% for HLP004. HLP003 represents approximately 96% of combined product rNPV.

1. 1Investment thesis
2. 2Company overview and corporate history
3. 3HLP003 design and pharmacokinetic rationale
4. 4HLP003 Phase 1/2a efficacy, safety, and follow-up
5. 5Phase 3 APPROACH, EMBRACE, and EXTEND studies
6. 6Major depressive disorder and current treatment approaches
7. 7HLP004 development and generalized anxiety disorder
8. 8HLP005 preclinical pipeline
9. 9Competitive landscape in depression and anxiety
10. 10Market opportunity and treatment infrastructure
11. 11Management and shareholder overview
12. 12Patient-based revenue assumptions and commercialization
13. 13Risk-adjusted valuation framework
14. 14Financial performance and funding outlook
15. 15Clinical, regulatory, commercial, and financing risks
16. 16Research disclosures

• Phase 3 results may not replicate the magnitude or durability of the early HLP003 signal.
• Trial unblinding, expectations, patient selection, or endpoint variability may affect interpretation.
• Clinical safety, controlled-substance requirements, and regulatory review could delay or prevent approval.
• HLP004 has not yet established efficacy against an inactive placebo, and competing programs are more advanced.
• Additional funding may be required, potentially leading to shareholder dilution or constrained development.
• Reimbursement, supervised treatment capacity, clinician adoption, and retreatment frequency may limit commercial uptake.
• Patent challenges, loss of exclusivity, manufacturing constraints, or supply disruptions could reduce future returns.
• Forecasts depend on uncertain assumptions about eligible patients, penetration, price realization, launch timing, and costs.